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Abstract
Background: S100A4 is a metastasis-associated protein which has been linked to multiple cellular
events, and has been identified extracellularly, in the cytoplasm and in the nucleus of tumor cells;
however, the biological implications of subcellular location are unknown. Associations between a
variety of posttranslational protein modifications and altered biological functions of proteins are
becoming increasingly evident. Identification and characterization of posttranslationally modified
S100A4 variants could thus contribute to elucidating the mechanisms for the many cellular
functions that have been reported for this protein, and might eventually lead to the identification
of novel drugable targets.
Methods: S100A4 was immuoprecipitated from a panel of in vitro and in vivo sources using a
monoclonal antibody and the samples were separated by 2D-PAGE. Gels were analyzed by western
blot and silver staining, and subsequently, several of the observed spots were identified as S100A4
by the use of MALDI-TOF and MALDI-TOF/TOF.
Results: A characteristic pattern of spots was observed when S100A4 was separated by 2D-PAGE
suggesting the presence of at least three charge variants. These charge variants were verified as
S100A4 both by western immunoblotting and mass spectrometry, and almost identical patterns
were observed in samples from different tissues and subcellular compartments. Interestingly,
recombinant S100A4 displayed a similar pattern on 2D-PAGE, but with different quantitative
distribution between the observed spots.
Conclusion: Endogenously expressed S100A4 were shown to exist in several charge variants,
which indicates the presence of posttranslational modifications altering the net charge of the
protein. The different variants were present in all subcellular compartments and tissues/cell lines
examined, suggesting that the described charge variants is a universal phenomenon, and cannot
explain the localization of S100A4 in different subcellular compartments. However, the identity of
the specific posttranslational modification and its potential contribution to the many reported
biological events induced by S100A4, are subject to further studies.
Published: 13 June 2008
BMC Cancer 2008, 8:172 doi:10.1186/1471-2407-8-172
Received: 20 December 2007
Accepted: 13 June 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/172
© 2008 Haugen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
Page 2 of 10
(page number not for citation purposes)
Background
S100A4 is a small (approximately 12 kDa) acidic calcium-
binding protein that has been associated with a range of
biological functions, such as cell migration, invasion and
angiogenesis, potentially contributing to higher meta-
static capacity of tumor cells [1-4]. In line with this,
increased expression of S100A4 has been correlated with
adverse prognosis in patients with various types of cancer
[5].
S100A4 belongs to the S100 protein family comprising at
least 20 members, of which all are exclusively expressed in
vertebrates. The human variant of S100A4 consists of 101
amino acids and is characterized by two calcium-binding
EF-hands connected by an intermediate region referred to
as the hinge region, and a distinct C-terminal extension.
The S100 protein family shows a high degree of sequence
homology, especially in the calcium binding EF-hand
regions, while the composition of the C-terminal exten-
sion and the hinge region is more diversified and thus
characterize each member [6,7]. Numerous studies indi-
cate that S100A4 is arranged as homodimers held together
by non-covalent bonds, and that this dimerization is
important for the biological function. Upon calcium
binding the homodimer undergo a conformational
change that leads to exposure of the hydrophobic regions
in the C-terminal end, initially buried in the complex [8].
S100A4 is located both in the cytoplasm, extracellularly
[9], and also in the nucleus of tumor cells [10], but the
mechanisms for transport and homing to subcellular
compartments remains largely unexplored. The protein
has also been found expressed in a variety of different nor-
mal cells [11]and the release of S100A4 into the extracel-
lular space may thus originate both from tumor and/or
stromal cells [12].
Most of the reported intracellular effects of S100A4 are
associated with cytoskeleton rearrangements that may
influence cellular motility [13-17], and extracellulary
added S100A4 has also been shown to boost migration of
astrocytic tumor cells [18]. In addition, the extracellulary
added protein may sensitize osteosarcoma cells to INF-γ
mediated apoptosis [19], and provoke degradation of the
extracellular matrix (ECM) by augmenting the levels of
matrix metalloproteinases [20]. The fact that S100A4
induces remodeling of the ECM suggests that the protein
may also affect angiogenesis [21]. The mechanism by
which S100A4 exerts its many reported and partly contra-
dictory biological functions is not well understood, but
one hypothesis could be that the protein exhibits different
functions depending on its subcellular localization and/
or posttranslational modifications.
A vast number of posttranslational protein modifications
(PTMs) have been described [22]. PTMs may result in
physiochemical changes of the protein with respect to
mass, charge, structure and conformation, and thereby
alter functional properties of the protein, such as binding
affinity, enzyme activity and protein hydrophobicity. As a
consequence, PTMs may target a protein for compartmen-
talization, degradation and protein-protein interactions.
During the last few years progression in genomic and pro-
teomic technology has pushed the limits of protein
knowledge and one has realized the functional impor-
tance of several novel PTMs other than the more com-
mon. As an example, human p53 has been reported to be
potentially post-translationally modified on at least 18
sites [23] including phosphorylation, acetylation and
sumoylation, with implications for DNA binding, stabil-
ity, oligomerization, nuclear import/export and ubiquiti-
nation [24].
The localization of S100A4 in the different cellular com-
partments suggests some type of subcellular targeting and
transport. The present study was undertaken to investigate
whether PTM of S100A4 could cause specific localization
of the protein. Such modifications could, through
increased calcium binding potential or altering the func-
tional C-terminal extension, also have impact on the bio-
logical function of the protein when localized in the
particular compartments. To study this we isolated
S100A4 from several tissues, cellular compartments and
also from recombinant sources and analyzed the protein
by 2D-PAGE and western blotting. The S100A4 identity of
several observed 2D spots were subsequently confirmed
by the use of mass spectrometry (MALDI-TOF).
Methods
Cell lines and cell culture
Human colorectal carcinoma cell lines HCT116 and
SW620 were purchased from ATCC (Manassas, VA) and
the OHS osteosarcoma cell line was established in-house
[25]. All cell lines were cultured in RPMI-1640 (Bio Whit-
taker, Verviers, Belgium) containing 10% fetal bovine
serum (PAA Laboratories GmbH, Pasching, Austria), 20
mM Hepes and 2 mM glutamax (GIBCO BRL Life Tech-
nologies, Paisley, UK). Cell cultures were routinely tested
negative for mycoplasma infection. Cells were detached
using EDTA (Bio Whittaker) and washed twice in PBS (Bio
Whittaker).
Patient samples
Tumor tissue was obtained from colorectal cancer patients
during primary surgery, snap-frozen in liquid nitrogen
and stored at -80°C. Eight tumor biopsies were selected
from a panel of primary colorectal carcinoma samples,
including two tumors from each Duke's stage (A, B, C and
D). All tumors expressed high levels of S100A4, as
assessed previously by immunohistochemistry, and
within each stage group, one tumor harboring wt and one
mutated TP53 were selected [10].BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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Isolation of red blood cells (RBC) and mononuclear cells 
(MNC)
Human red blood cells and mononuclear cells were iso-
lated from whole blood samples from healthy donors.
Red blood cells were isolated by gradient centrifugation
using CPT tubes (Becton Dickinson Co., Franklin Lakes,
NJ) according to the manufacturers' instruction, and the
fraction below the gel was collected. Mononuclear cells
were isolated by Lymphoprep density centrifugation
(Medinor, Oslo, Norway) according to the manufacturers'
instructions and collected from the interphase layer. Pro-
tein isolation was performed as described below.
Recombinant S100A4
One of the human recombinant S100A4 variants was
from Jena Biosciences (Jena, Germany), the second was a
kind gift from Prof. E. Lukanidin (Danish Cancer Society,
Copenhagen, Denmark), and the third was produced in-
house by the use of the prokaryot expression vector pGEX
3X (GE Lifesciences, Uppsala, Sweden) inserting the
S100A4 sequence into the BamHI site and purified using
Glutathione Sepharose 4B (GE Lifesciences). The GST-tag
was cleaved by Factor Xa treatment and subsequent puri-
fication using the Factor Xa cleavage capture kit (Novagen,
La Jolla CA), all according to the manufacturers protocol.
The resulting recombinant S100A4 contains Glycine, Iso-
leucine and Proline C-terminally in addition to the native
human sequence. Mouse recombinant S100A4 was pro-
duced using the E. coli vector pQE30 (Qiagen, Hilden,
Germany) using the BamHI insertion site which resulted
in C-terminal attachment of RGS-6xHis and Proline-
Arginine to the native mouse sequence. The recombinant
mouse S100A4 was purified using Talon Metal Affinity
Resin (Clontech, Mountain View, CA), according to the
manufacturers' protocol. All proteins were stored in PBS at
-70°C.
Preparation of protein lysates
Preparation of whole cell lysates was performed by addi-
tion of lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH
7.5, 0.1% NP-40, 10 μg/ml of each leupeptin hemisulfate,
aprotinin, pepstatin A, 20 mM β-glycerolphosphate, 1
mM PMSF, 1 mM sodium orthovanadate and 100 mM
sodium fluoride) to dry cell pellets, left on ice for 1 h, son-
icated and centrifuged to remove cell debris.
Extracellular protein fractions were prepared by collecting
growth medium from confluent grown SW620 cells. The
collected growth medium was analyzed for dead/lysed
cells by measuring levels of the intracellular constituent
lactate dehydrogenase (data not shown). Finally the con-
ditioned growth medium was concentrated by reducing
the volume to 1/10 in a rotavapor (Thermo Savant,
Waltham, MA) and desalted using Zeba Desalt Spin Col-
umns (Pierce, Rockford, IL).
Sub-fractioning of nuclear and cytoplasmic components
was performed essentially as previously described [26]
with some modifications. Cells were mixed with buffer B
(340 mM trisodium citrate, 100 mM NaCl and 1% Tri-
ton), left on ice for 30 min. and homogenized in a Potter-
Elvehjem homogenizer (10 strokes at 2000 rpm). The
homogenate was mixed with cold STKM buffer (250 mM
sucrose, 50 mM Tris-HCl pH 7.5, 25 mM KCl and 5 mM
MgCl2) and the nuclear fraction isolated by centrifugation
(37000 rpm for 30 min in a 55Ti rotor at 4°C). The super-
natant (cytoplasmic fraction) was collected and nuclear
lysates prepared as described above. Purity of the fractions
was assessed by western blot, staining for α-tubulin as
cytoplasmic marker (CP06, Calbiochem, San Diego, CA)
and lamin B as nuclear marker (NA12, Calbiochem) as
described in detail previously [10].
Frozen tissue samples (15–24 mg) were blended in lysis
buffer (20 mM Tris pH 7.5, 137 mM NaCl, 100 mM
sodium fluoride, 10% glycerol, 1% NP-40, 10 μg/ml leu-
peptin hemisulfate, aprotinin, pepstatin A, 20 mM β-glyc-
erophosphate, 1 mM PMSF, 1 mM sodium
orthovanadate) using a homogenizer (IKA Labortechnik,
Staufen, Germany), left on ice for 1 h, sonicated and then
centrifuged to remove cellular debris.
Protein concentration from all lysates, except from red
blood cells due to hemoglobulin interference, was esti-
mated using BCA Protein Assay Kit (Pierce) and lysates
were stored at -80°C until use.
Immunoprecipitation (IP)
An in-house monoclonal antibody MAb 20.1 [27] was
coupled to CNBr activated Sepharose 4B (GE Lifesciences)
according to the manufacturer's protocol and stored in
20% EtOH solution at 4°C. The protein lysate was mixed
with 60 μl conjugated beads and IP buffer (300 mM NaCl,
0.25% Na-lauroyl sarcosin, 0.45% Na-deoxy cholate, 100
mM Na-phosphate buffer pH 8.2) and incubated with
rotation at 4°C over night. After a short spin in a bench
top centrifuge the supernatant was discarded and the
beads washed twice in IP buffer and transferred to Spin-X
Centrifuge Tube Filter 0.22 μm (Corning Incorporated,
Corning, NY). The precipitate was eluted in H2O by heat-
ing at 95°C for 1 minute and spinning for 2 minutes at
4000 rpm, followed by desalting using Zeba Desalt Spin
Columns (Pierce) and finally concentrated in a rotavapor
(Thermo Savant, Waltham, MA).
2D-gel electrophoresis and staining
2D-gel electrophoresis was performed using the ZOOM
IPG-Runner System (Invitrogen, Carlsbad CA, USA) with
immobilized pH gradient (IPG) strips pH 4–7 and gradi-
ent SDS-PAGE 4–12% in 2-(N-morpholino)ethanesul-
fonic acid (MES) buffer. All procedures were performedBMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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according to the manufacturer's protocol, which includes
reduction and alkylation of cysteine residues. De-ionizing
of urea (Kodak, Rochester, NY), used in the sample rehy-
drating buffer, was performed where indicated by addi-
tion of mixed-bed resin (BioRad, Hercules, CA). The
proteins were transferred to a 0.22 μm polyvinylidine dif-
luoride membrane (Millipore Corporation, Bedford, MA)
in a Mini Trans-Blot Cell (BioRad). Detection of S100A4
was performed as previously described using an in-house
produced monoclonal antibody MAb 22.3 [27] or a com-
mercially available polyclonal antibody (DAKO, Glos-
trup, Denmark). Silver staining and destaining were
essentially performed as previously described [28]. When
recombinant protein was run on 2D-PAGE, a small por-
tion of antibody was mixed in the sample for alignment
with previous results where S100A4 was isolated by
immunoprecipitation.
MALDI-TOF preparation and analysis
Spots of interest were excised from silver stained 2D-
PAGE, destained and washed twice (25 mM NH4HCO3,
50% acetonitrile) before samples were subjected to in gel
protein digestion using sequence grade modified trypsin
(Promega, Madison, WI). Reduction and alkylation was
performed during 2D-PAGE, and was consequently not
repeated. Peptides were extracted in a mixture of Trifluor-
oacetic acid (TFA) and acetonitrile, concentrated and
desalted using C18 affinity material (Empore Extraction
disks, 3 M, St. Paul, MN) assembled in a pipette tip, mixed
with  α-cyano-4-hydroxycinnamic acid (Fluka/Sigma-
Aldrich, St. Louis, MO) and spotted on a 384-well steel
AnchorChip sample plate (Bruker Daltonics, Billerica,
MA). Prior to desalting, some peptide samples were also
treated using ProteoMass Guanidation Kit (Sigma-
Aldrich, St. Louis, MO) according to the manufacturer's
protocol. MS analysis was carried out in an Ultraflex®
MALDI-TOF/TOF instrument (Bruker Daltonics) and the
obtained spectra analyzed in the FlexAnalysis software.
Electro-elution from 2D-PAGE
20 μg of recombinant S100A4 were run on two identical
2D-PAGEs of which one was stained with coomassie-blue
(Fermentas, Burlington, ON) to use as template for cut-
ting out spots of interest from the untreated gel. Protein
from the excised spots was eluted in ElutaTube (Fermen-
tas) using running buffer (200 mM glycine, 2 mM Tris-
HCl, 0.025% SDS) at 100 V for 60 minutes. The samples
were then precipitated according to the manufacturer's
protocol, air dried and re-suspended in H2O. Re-running
of 2D-PAGE was performed as described above.
Computerized prediction algorithms for phosphorylation 
and deamidation
The primary amino acid sequence of S100A4 in FASTA
format (SwissProt entry P26447) was submitted (accessed
Nov. 2006) to the NetPhos 2.0 Server [29], which returns
prediction scores between 0 and 1 for possible phosphor-
ylations on Serine, Threonine and Tyrosine residues. Sim-
ilarly, the solution structure of S100A4 (PDB entry 1m31)
[30] was submitted to the Deamidation CD and ID Search
Form (accessed Nov. 2006) [31], which calculates a CD
score for each Asparagine residue reporting their predicted
half life in 0.15 M Tris-HCl buffer pH 7.4 at 37°.
Results
Characteristic distribution pattern of human S100A4 when 
separated by 2D-PAGE
A characteristic pattern of spots was observed when
S100A4 immunoprecipitated from SW620 cell lysate was
separated by 2D-PAGE, blotted and stained with anti-
S100A4 (Fig. 1). At least three, in some cases four, distinct
spots were observed corresponding to the expected molec-
ular mass of the protein. The position of the most intense
spot was consistent with the theoretical mass and isoelec-
tric point (pI) of human S100A4 as predicted by Prot-
Param on the Expasy web page (MW = 11728, pI = 5.85).
A trail of two or three gradually less intense spots sepa-
rated by approximately 0.2–0.3 pH units were observed
towards the more acidic end, with the most acidic spot
located at pH 4. Furthermore, when cytoplasmic and
nuclear fractions isolated from in vitro cultured SW620
cells were compared with extracellular protein by similar
analysis, almost identical distribution patterns were
observed (Fig. 1A).
Previously, expression of S100A4 was suggested to
depend upon p53 mutational status [32], and it was there-
fore of interest to examine whether this could be of impor-
tance for the observed distribution pattern on 2D-PAGE.
By comparing immunoprecipitated S100A4 from
HCT116 with the above results from SW620 no apparent
differences between cell lines harboring wild-type and
mutated TP53, respectively, were revealed. In addition,
when examining S100A4 from the osteosarcoma cell line
OHS, the same pattern was observed (Fig. 1B).
Although a consistent 2D-PAGE distribution pattern was
observed in all the samples from the two cell lines, differ-
ent results might be expected when analyzing patient
material. In vitro cell culture lack the contribution from
the normal microenvironment, and changes in the genetic
profile may also be induced due to long term cultivation.
When immunoprecipitated protein from a panel of eight
primary colorectal carcinoma biopsies was examined by
2D-PAGE, no clear differences compared to the in vitro
samples were detected, except for variations attributable
to varying amounts of total S100A4. Moreover, no differ-
ences were observed according to tumor stage or TP53
mutational status as indicated by the representative sam-
ples shown in Fig. 1C.BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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Western blot of S100A4 separated by 2D-PAGE Figure 1
Western blot of S100A4 separated by 2D-PAGE. S100A4 was immunoprecipitated from the complex samples using 
MAb 20.1 and blotted onto PVDF filters. The western blots are visualized by staining with MAb 22.3 against S100A4 and aligned 
according to the antibody light chain (not shown) detached during the immunoprecipitation procedure or added directly into 
the recombinant samples. A. Comparison of S100A4 in nuclear and cytoplasmic fractions isolated from in vitro cultured color-
ectal cancer cell line SW620 and extracellular S100A4 from conditioned growth medium by confluently growing SW620 cells. 
B. Comparison of S100A4 isolated from whole cell lysate of two in vitro cultured colorectal cancer cell lines with different TP53 
status, SW620 (TP53 mut) and HCT116 (TP53 wt), and the OHS osteosarcoma cell line. C. Analysis of S100A4 isolated from 
biopsies collected from colorectal cancer patients diagnosed with different p53 status and Duke's stage. Two representative 
samples out of eight analyzed are shown. D. Endogenous S100A4 isolated from red blood cells (RBC) and mononuclear cells 
(MNC). E. Recombinant human S100A4 produced in-house using vector pGEX 3X (with removal of GST-tag).BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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2D patterns of S100A4 from normal cells and recombinant 
sources
Having observed several presumably modified forms of
S100A4 in cancer cells it was of interest to examine
whether this was the case also in normal human cells. In
previous studies, RBC [27] and MNC [33,34] were found
to have high expression of the protein. When S100A4 was
immunoprecipitated from these normal cells and ana-
lyzed by 2D-PAGE the same distribution as described for
S100A4 isolated from cancer cells was observed (Fig. 1D).
In contrast, when recombinant human S100A4 produced
in E. coli was separated by 2D-PAGE and visualized as
before, a rather similar 2D pattern to the one previously
observed for human endogenously expressed protein was
obtained, but with considerable differences in the quanti-
tative distribution between the spots (Fig. 1E). Separation
into more than one spot was also observed for other
recombinant S100A4, encoding either the human or
mouse variant, but all produced in E. coli (Fig. 2).
To exclude the possibility that the observed pattern could
have resulted from changes introduced during sample
processing, two control experiments was performed. First,
in-house produced human recombinant S100A4 was sub-
jected to 2D-PAGE, extracted from one intense spot, re-
run on 2D-PAGE and stained with MAb 22.3. The result of
this visualization was a single spot located at the same
MW and pI as the extracted spot (data not shown). Fur-
thermore, carbamylation of proteins by isocyanic acid, a
degradation product of urea, could also increase net neg-
ative charge and thus result in the observed pattern. How-
ever, running two samples of endogenous S100A4 in
parallel, one where all degradation products of urea was
cleared away by using mixed bed resin prior to mixing
with S100A4, and one with no clearing, resulted in iden-
tical patterns. These two experiments indicated that our
handling procedures did not induce modifications in the
protein sequence that could cause the observed pattern on
the 2D-PAGE.
Verification of 2D spots as S100A4
Although the antibodies against S100A4 used for immu-
noprecipitation and western blot analyses (MAb 20.1 and
MAb 22.3) both have been proven to be highly specific,
the risk of false positive results because of cross reactivity
cannot be excluded. Thus, to further confirm the identity
of the detected S100A4 variants, regions of interest were
excised from gels and in-gel tryptic digestion performed,
upon which peptides were extracted and run on MALDI-
TOF. When necessary for identification, MALDI-TOF/TOF
was run on a peptide, representing amino acids 8–18 of
the 101 in total for S100A4. When analyzing the produced
mass list through Mascot [35] using peptide mass finger-
printing (PMF) and MS/MS fragment ion series towards
the SwissProt library, a score corresponding to p < 0.05 for
match in the library (SwissProt entry P26447) was consid-
ered as a positive identification. Using this strategy, two
excised spots from SW620 whole cell lysate, three from a
primary colorectal carcinoma biopsy and two from in-
house produced recombinant S100A4 were confirmed to
contain human S100A4. All these identified spots are
indicated in a schematic presentation (Fig. 3A–C).
When pooling every detected tryptic peptides from all
samples, these correspond to the entire list of theoretically
predicted peptides of S100A4 in the range of 500–2000
Da (Fig. 3D). However the coverage of the S100A4 amino
acid sequence was subject to variations in the range of 30–
50% in the different experiments and the measured m/z
of some tryptic peptides could be attributed to more than
one theoretically predicted peptide sequence within
S100A4.
The S100A4 amino acid sequence was analyzed with
respect to two possible modifications using web based
PTM prediction algorithms. The analysis returned three
Serine residues, S20, S60 and S64 with scores of 0.997,
0.846 and 0.996, respectively, suggesting that these resi-
dues have high probability of being phosphorylated. Fur-
thermore, analysis of the solution structure of S100A4
revealed three potentially unstable Asparagine residues
N65, N68 and N87 with CD values of 8.293, 21.696 and
2D-PAGE distribution pattern of a panel of recombinant (E.  coli) S100A4 proteins Figure 2
2D-PAGE distribution pattern of a panel of recom-
binant (E. coli) S100A4 proteins. One μg recombinant 
protein was separated by 2D-PAGE and visualized by west-
ern blots staining with a polyclonal antibody recognizing both 
mouse and human S100A4. A: Human S100A4 produced in-
house using vector pGEX 3X with removal of GST-tag (pre-
viously shown in fig. 1E). B: Human his-tagged S100A4 pro-
duced in the lab of Prof. E. Lukanidin (Danish Cancer 
Society). C: Human S100A4 produced by Jena Biosciences. 
D: Mouse his-tagged S100A4 produced in-house using vector 
pQE30.BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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13.500, respectively, which suggests that these residues
could be subject to deamidation. The S100A4 amino acid
chain and location of predicted modifications are sche-
matically illustrated (Fig. 3D).
Discussion
In the present work we have demonstrated that endog-
enous human S100A4 distributes in a characteristic pat-
tern when separated by 2D-PAGE, and irrespective of
source or subcellular compartment used for immunoiso-
lation of the protein, the observed pattern was almost
identical. Interestingly, a similar pattern, but with differ-
ent quantitative distribution, was observed when analyz-
ing different batches of recombinant S100A4. The identity
of several examined spots was confirmed for the first time
by mass spectrometric methods, verifying the existence of
at least three charge variants of S100A4. The most likely
interpretation of the presence of these different charge var-
iants is that S100A4 is posttranslationally modified, since
changes introduced during sample processing was largely
excluded.
Immunoprecipitated human S100A4 was separated by
2D-PAGE in at least three (in some cases four) distinct
spots of equivalent mass but with different charge. A com-
parable observation, although verified only by immuno-
logical methods, was made when S100A4 from tumor
interstitial fluid from breast cancer patients was separated
by 2D-PAGE [11]. Furthermore, in a recently published
study on p53-related changes, two different PTMs of
S100A4 were indicated by SELDI-TOF-MS [36]. These
modifications, glutathionylation and cysteinylation,
could theoretically have caused the distribution pattern
observed in this study, however preliminary experiments
indicate that this is not the case.
The finding that human S100A4 isolated from primary
colorectal carcinomas, cell lines and normal cells resulted
in similar patterns is remarkable and suggests that the
observed 2D-PAGE distribution is a general phenome-
non. This was also underscored by the identification of an
almost identical pattern when the protein was isolated
from nuclear, cytoplasmic and extracellular compart-
ments. This is unanticipated since PTM often is transiently
present and the occurrence is frequently time-, location-
and site specific [37].
Surprisingly, all four recombinant S100A4 proteins exhib-
ited more than one charge variant when separated by 2D-
PAGE. Because of its relative ease in manipulation, E. coli
has emerged as the most common hosts for heterologous
protein production, however, one major disadvantage
hamper its use; the inability to introduce important PTMs
such as glycosylation, phosphorylation and acylation,
which may be essential for biological activity [38]. In con-
trast to the pattern observed for endogenous S100A4,
none of the recombinant proteins clearly displayed the
characteristic picture of one main spot followed by gradu-
ally less intense spots, which would be expected for pro-
teins altered by sequential PTMs. The choice of cloning
strategy may result in the addition of extra amino acids
and affinity tags on recombinant proteins that could
influence 2D-PAGE migration patterns, potentially com-
plicating the interpretation of such data; however, one
might expect that the final protein distributed in one sin-
gle spot. The observed variable distribution could possi-
bly be linked to differences in biological effect when using
different recombinant proteins. In theory, the observed
distribution pattern of the recombinant variants could be
caused by heterogeneous cleavage of the selection tags
(GST/His) or by unspecific degradation, but examination
of undigested samples by MALDI-MS did not support
such an explanation (data not shown).
Since immunological methods depend on antibody spe-
cificity and the S100 protein family exhibits high
sequence homology, the confirmation of the present
results by non-immunological methods was warranted.
Using MALDI-TOF mass spectrometry to analyze tryptic
peptides from excised gel spots, the identity of several
Charge variants identified as S100A4 by MALDI-TOF,  detected tryptic peptides, and location of predicted PTMs Figure 3
Charge variants identified as S100A4 by MALDI-
TOF, detected tryptic peptides, and location of pre-
dicted PTMs. A-C: Schematic representation of the differ-
ent spots obtained from various sources confirmed as 
S100A4 by MALDI-TOF and MALDI-TOF/TOF. All shown 
spots are identified in the SwissProt library as S100A4 with p 
< 0.05. A: In vitro cultured HCT116. B: Tumor biopsy from a 
colorectal cancer patient. C: Human recombinant S100A4 
produced in-house. D: Representation of the S100A4 amino 
acid sequence with all tryptic peptides discovered on 
MALDI-TOF (boxes) and location of phosphorylations (P) 
and deamidations (D) predicted by computer algorithms.BMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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spots reproducibly confirmed the results obtained by
western blotting. Unfortunately, we have so far not been
able to identify and further characterize the present PTMs.
One possible explanation could be that the modified frag-
ments were undetectable since the sequence coverage of
this small protein was only between 30 and 50%. Also,
trypsin digestion might cleave potentially interesting parts
of the molecule into fragments that are too small for fur-
ther analysis. We are in the process of establishing proto-
cols using other digestive enzymes and MALDI-matrixes
ensuring better coverage of the protein sequence.
Although the actual PTMs have not been identified, the
observed 2D pattern gives several indications with respect
to the type of the putative modifications. Since the appar-
ent mass did not change significantly between the spots,
all PTMs introducing heavy residues or major deletions in
the amino acid sequence can be excluded. Furthermore,
the visual impression of the 2D pattern suggests the pres-
ence of one quantitatively dominating variant, with less
abundant variants distributing towards lower pH, which
could indicate either successive loss of positive charges or
gain of negative charges, resulting in gradually more
acidic forms of the protein. Even with these limitations a
large number of PTMs are possible from a physicochemi-
cal point of view, and although a comprehensive analysis
cannot be made, it is tempting to speculate on a few of the
more likely alternatives. Phosphorylation introduces a
negative charge on Serine, Threonine or Tyrosine residues
while only changing the mass by 80 Da. Analyzing the
S100A4 amino acid sequence in NetPhos revealed three
Serine residues as likely phosphorylation sites, and the
observed 2D pattern match well with the predicted pat-
tern if such modifications were present. Another possible
modification that would introduce a negative charge with
minimal mass change is deamidation, in which Asparag-
ine or Glutamine is converted to Aspartic or Glutamic
acid. A prediction algorithm for deamidation of S100A4
suggested the presence of three labile Asparagines which,
if sequentially deamidated, theoretically would produce a
2D pattern similar to the one observed in our experi-
ments. Another frequently occurring PTM involves cleav-
age of peptide residues resulting in loss of amino acids
either from the N- or C-terminal end. Such loss of the
three most C-terminal amino acids in S100A4 might also
explain the observed pattern. All three PTMs suggested
above could potentially have an impact on biological
function, subcellular targeting or protein interaction of
S100A4.
It is becoming increasingly evident that PTMs may be
involved in the modulation of protein synthesis, degrada-
tion, activity, and molecular interactions, of which all
may have implications for multiple cellular events
[39,40]. S100A4 has been associated with many biologi-
cal functions, some of which are probably related to local-
ization in specific tissues and cellular compartments, and
it may be possible that PTMs could be a permissive
requirement for the exertion of some of the functions
attributed to this protein.
Given the high sequence homology within the S100 fam-
ily, modifications observed in other S100-proteins might
also be relevant for S100A4, even if individual family
members have discrete functions and tissue distribution.
The S100A11 protein has been found translocated to the
nucleus upon phosphorylation [41], and we therefore
hypothesized that phosphorylation could also be
involved in translocating S100A4 to the nucleus. The
observed comparable distribution pattern of S100A4
from different compartments would in principle argue
against such hypothesis. However, even with apparent
qualitative similarity in observed 2D patterns subtle quan-
titative differences, not apparent by western blot or silver
staining analysis, might exist between corresponding
spots from different sources, reflecting stochiometric vari-
ation of unmodified and modified S100A4. Recently, the
modification of S100A8 and S100A9 by introduction of
Nε-carboxymethyllysine was demonstrated to be associ-
ated with sustained intestinal inflammation through
NFκB activation [42]. The addition of extracellular
S100A4 has been shown to induce NFκB activity in a low
S100A4 expressing osteosarcoma cell line [19], but the
possibility of a PTM being involved in such activation has
yet to be explored.
At present we do not know which PTMs are present in
S100A4 or the location in the amino acid sequence, but
speculations regarding the purpose of possible PTMs can
be made. PTMs in the hinge region could affect steric
properties, while changes to the C-terminal end, which is
exposed upon calcium binding, could directly affect the
proteins interacting capabilities. Both hinge and C-termi-
nal regions have, based on their heterogeneity in the
S100-family [8], been proposed to be important for the
biological activity of each S100-protein [43], which fur-
ther suggests that PTMs in these regions might also be spe-
cific to each S100-protein. One of the main features of the
S100-proteins is their calcium binding motifs, the EF-
hands, and which have also been shown to be important
for dimerization and biological functions [6], is also the
most conserved region among the S100 family members.
PTMs introducing a negative charge or neutralizing an ini-
tially positive charge could potentially increase the cal-
cium binding affinity [8], and the 2D pattern observed for
S100A4 with gradually more acidic variants could thus
suggest increased calcium binding capacity. For S100A9
and S100A12, phosphorylation of at least two different
amino acids was shown to induce augmented calcium
binding, which subsequently led to plasma membraneBMC Cancer 2008, 8:172 http://www.biomedcentral.com/1471-2407/8/172
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translocation of the proteins [44]. Since the calcium-bind-
ing domains are highly conserved, a general PTM that
affects several of the S100-members could be possible.
However, posttranslational modifications made directly
to the EF-hands in the family of EF-hand proteins have to
our knowledge not yet been described, and would there-
fore be of great interest in an even broader perspective.
Conclusion
Endogenously expressed S100A4 was demonstrated to
exist in several charge variants, indicating the presence of
posttranslationally modified forms of the protein. These
charge variants appeared to be universially present in
S100A4 isolated from different subcellular compartments
and tissues. As part of the emerging field of oncoproteom-
ics, PTMs are proving to be increasingly relevant for the
understanding of cancer biology and as potential druga-
ble targets [45,46]. S100A4 has in numerous studies
already been established as an important determinant of
cancer metastasis, and potential PTMs may be of relevance
for determining the biological processes resulting in
increased metastatic capacity. Further efforts will be made
to discover the nature of the PTMs present in S100A4 by
optimizing mass spectrometry strategies and to further
screen for eventual differential presence of the PTM using
2-D Fluorescence Difference Gel Electrophoresis (DIGE).
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